As France Extends Its Medical Marijuana Trial, Aurora And Ethypharm Continue To Be Its Exclusive Suppliers

Aurora Europe GmbH, a subsidiary of Aurora Cannabis Inc. ACB ACB, and Ethypharm have once again been selected by the French General Directorate of Health (DGS) as exclusive suppliers of dried medical cannabis flower until the end of the French trial period. The trial has recently been extended until March 2024.

"We are delighted to have been selected once again to continue to supply high quality dried medical cannabis flower to the French pilot program. Driven by our purpose of opening the world to cannabis, Aurora continues to work hand-in-hand with government officials, physicians and pharmacists to reduce stigma and further develop medical markets throughout Europe," stated Dr. Axel Gille, president of Aurora Europe.

Aurora and Ethypharm signed an agreement to serve the French pilot program, led by the National Agency for the Safety of Medicines and Health Products, in October 2020, leveraging both parties' expertise. Under the terms of the exclusive partnership, Aurora supplies medical cannabis, as well as EU GMP manufacturing and logistics support. Distribution and pharmacovigilance activities continue to be handled by Ethypharm Laboratories, Ethypharm's French sales subsidiary.

Within the framework of the extension of the trial, the DGS opened a call for tenders to supply medical cannabis in January 2023. In March, Aurora Europe and Ethypharm were selected to continue to provide medical cannabis produced according to European GMP standards to patients included in the study.

Photo: Benzinga edit with photos by jarmoluk and lindsayfox on Pixabay

Market News and Data brought to you by Benzinga APIs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Cannabis rescheduling seems to be right around the corner